AMOYTOP(688278)2025-01-15 10:37Financial Performance Forecast - The company expects a net profit attributable to shareholders of the parent company for 2024 to be between 810 million and 840 million CNY, representing a year-on-year increase of 25.46 million to 28.46 million CNY, or a growth of 45.83% to 51.23%[4] - The projected net profit attributable to shareholders after deducting non-recurring gains and losses is estimated to be between 805 million and 835 million CNY, reflecting an increase of 22.56 million to 25.56 million CNY, or a growth of 38.94% to 44.12% compared to the previous year[4] - In 2023, the company achieved a total profit of 640.65 million CNY and a net profit attributable to shareholders of 555.45 million CNY, with a basic earnings per share of 1.37 CNY[5] Business Stability and Growth - The company's main business remains stable and is expected to grow significantly due to the increasing recognition of its product, Pegbivac, as a first-line antiviral treatment for chronic hepatitis B[6] Performance Forecast Validity - The performance forecast is based on preliminary calculations by the company's finance department and has not yet been audited by a registered accountant[7] - The company has not identified any significant uncertainties that could affect the accuracy of the performance forecast[7] - Investors are advised that the forecast data is preliminary and the final audited financial data will be disclosed in the official annual report for 2024[8]